Biota Announces Relenza Royalty for December 2009 Quarter
February 04 2010 - 7:43PM
Business Wire
Biota Holdings Limited (ASX:BTA) today announced that it had
received written notification from GlaxoSmithKline that Relenza
sales were $462 million and indicative royalties were $32.6
million, for the three months ended 31 December 2009. The figures
were calculated on an Australian dollar exchange rate of 1.8182 to
the UK pound, although the actual payment will be calculated on
exchange rates at 30 April 2010.
Biota will report first half indicative Relenza royalty income
of $56.7 million (2008: $3.8m) when it releases its Interim Report
on 17 February 2010.
About Biota
Biota is a leading anti-infective drug development company based
in Melbourne Australia, with key expertise in respiratory diseases,
particularly influenza. Biota developed the first-in-class
neuraminidase inhibitor, zanamivir, subsequently marketed by
GlaxoSmithKline as Relenza. Biota research breakthroughs have
included novel nucleoside analogues designed to treat hepatitis C
virus (HCV) infections, licensed to Boehringer Ingelheim, and a
series of candidate drugs aimed at treatment of respiratory
syncytial virus (RSV) disease. Biota has clinical trials underway
with its lead compound for human rhinovirus (HRV) infection in
patients with compromised respiration or immune systems.
In addition, Biota and Daiichi Sankyo co-own a range of second
generation influenza anti-virals, of which the lead product
laninamivir, is in late stage clinical development.
Relenza™ is a registered trademark of the GlaxoSmithKline group
of companies.
*Further information available at www.biota.com.au
Biota Holdings (ASX:BTA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biota Holdings (ASX:BTA)
Historical Stock Chart
From Jul 2023 to Jul 2024